Longitudinal Trends of Urologic Malignancy After Solid Organ Transplantation at a High-Volume Transplant Center.
4 affiliations
- 1Department of Urology, Medical University of South Carolina, Charleston, USA.
- 2Department of Urology, Moffitt Cancer Center, Tampa, USA.
- 3Department of Public Health Sciences, Medical University of South Carolina, Charleston, USA.
- 4Department of Urology, Thomas Jefferson University, Philadelphia, USA.
Abstract
Introduction Since the advent of solid organ transplantation, there have been many concerns related to the risks of immunosuppression and malignancy. The impact of transplantation on cancer risk warrants continued evaluation of contemporary malignancy patterns. We assessed current trends at our high-volume transplant center. Methods A single-center retrospective analysis was performed at a high-volume transplant center in South Carolina for adult patients with a history of solid organ transplant who subsequently had a new urologic malignancy between 2008 and 2023. The malignancies were delineated with International Classification of Diseases, 10th Revision (ICD-10) codes for the bladder, urethra, ureter, renal pelvis, kidney, prostate, adrenal, penis, and testis. Demographic, transplant, and malignancy data were analyzed. Outcomes were analyzed for mortality rate, and univariate survival analysis was performed. Results Eighty-one patients met the inclusion criteria. The mean age at transplant was 56 years, and the mean age at cancer diagnosis was 60 years. The breakdown of cancers from most to least common was prostate (41%, 33), kidney (38%, 31), bladder (19%, 15), upper tract urothelial (1%, 1), and urethra (1%, 1). The mortality rate was 0.06 for urothelial, 0.05 for kidney, and 0.02 for prostate, compared with national averages of 0.005, 0.005, and 0.011, respectively. Survival analysis demonstrated significantly decreased survival for patients with urothelial malignancy after transplant compared with prostate cancer (p<0.01). Conclusions We found a significantly increased proportion of kidney and bladder malignancy in transplant patients in comparison to the South Carolina and national yearly incidence of these cancers in our single-institution high-volume transplant center.
Related
- Heart Transplantation: A Review of Recent Advancements in Pre-, Peri, and Post-Transplant Screening and Management
- Kidney transplantation in multiple myeloma: patient selection, timing, and post-transplant challenges in the modern therapeutic era
- Pre-Transplant Laboratory Parameters and Early Outcomes in HBV-Related Deceased Donor Liver Transplantation
- Renal Transplantation in Recipients With Modified Lower Urinary Tract: A Systematic Review and Implications for Adult Transplant Practice
- Atypical Spontaneous Cecal Perforation During Redo Kidney Transplant Post Heart-Kidney Transplantation.
BibTeX
@article{yankelevich2026longitudinal,
title = {{Longitudinal Trends of Urologic Malignancy After Solid Organ Transplantation at a High-Volume Transplant Center.}},
author = {Gabrielle R Yankelevich and Luis G Medina and J Peyton Vaughan and McKenzie Needham and Emma Bryant and Jennifer Drerup and Jean-Sebastien Anoma and Elizabeth Hill and Nicholas Zurinaga and Nikhil Anandpura and Vineeth Sama and Stephen J Savage},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116771},
url = {https://europepmc.org/article/MED/42921000},
note = {CC BY},
}
RIS
TY - JOUR
TI - Longitudinal Trends of Urologic Malignancy After Solid Organ Transplantation at a High-Volume Transplant Center.
AU - Gabrielle R Yankelevich
AU - Luis G Medina
AU - J Peyton Vaughan
AU - McKenzie Needham
AU - Emma Bryant
AU - Jennifer Drerup
AU - Jean-Sebastien Anoma
AU - Elizabeth Hill
AU - Nicholas Zurinaga
AU - Nikhil Anandpura
AU - Vineeth Sama
AU - Stephen J Savage
PY - 2026
DA - 2026/09/23
JO - Cureus
DO - 10.7759/cureus.116771
UR - https://europepmc.org/article/MED/42921000
AB - Introduction Since the advent of solid organ transplantation, there have been many concerns related to the risks of immunosuppression and malignancy. The impact of transplantation on cancer risk warrants continued evaluation of contemporary malignancy patterns. We assessed current trends at our high-volume transplant center. Methods A single-center retrospective analysis was performed at a high-volume transplant center in South Carolina for adult patients with a history of solid organ transplant who subsequently had a new urologic malignancy between 2008 and 2023. The malignancies were delineated with International Classification of Diseases, 10th Revision (ICD-10) codes for the bladder, urethra, ureter, renal pelvis, kidney, prostate, adrenal, penis, and testis. Demographic, transplant, and malignancy data were analyzed. Outcomes were analyzed for mortality rate, and univariate survival analysis was performed. Results Eighty-one patients met the inclusion criteria. The mean age at transplant was 56 years, and the mean age at cancer diagnosis was 60 years. The breakdown of cancers from most to least common was prostate (41%, 33), kidney (38%, 31), bladder (19%, 15), upper tract urothelial (1%, 1), and urethra (1%, 1). The mortality rate was 0.06 for urothelial, 0.05 for kidney, and 0.02 for prostate, compared with national averages of 0.005, 0.005, and 0.011, respectively. Survival analysis demonstrated significantly decreased survival for patients with urothelial malignancy after transplant compared with prostate cancer (p<0.01). Conclusions We found a significantly increased proportion of kidney and bladder malignancy in transplant patients in comparison to the South Carolina and national yearly incidence of these cancers in our single-institution high-volume transplant center.
SN - 2168-8184
ER -